---
title: "Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength"
date: "2025-02-13 03:51:10"
summary: "Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/12/EW.png"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025.

[benzinga](https://www.benzinga.com/general/health-care/25/02/43672055/heart-devices-focused-edwards-lifesciences-confident-in-2025-outlook-analyst-sees-long-term-strength)
